Gemfibrozil Tablet
Product Images NDC 50090-5808

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gemfibrozil (NDC 50090-5808). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Additional Adverse Reactions (Additional Adv Drug Reactions)

This appears to be a list of potential side effects of a medication. The medication name is not provided, but the list includes effects on various bodily systems such as the gastrointestinal, cardiovascular, central nervous, and genitourinary systems. It also mentions effects on clinical laboratory results and the immune system. Some of the listed side effects include weight loss, cardiac arrhythmias, liver dysfunction, confusion, paresthesia, decreased libido, and skin reactions like dermatitis and alopecia. It is important to note that this is not a complete list and that these side effects may not occur in all patients.*

FDA Label Image

Adverse Reactions (Adv Reactions)

This is a table showing the frequency of adverse events experienced by subjects taking Gemfibrozil and placebo respectively. It indicates the percentage of subjects who experienced various gastrointestinal reactions, dyspepsia, abdominal pain, acute appendicitis, atrial fibrillation, diarrhea, fatigue, nausea/vomiting, eczema, rash, vertigo, constipation and headache.*

FDA Label Image

Struct (Structure Gemfibrozil)

FDA Label Image

Table1 (Table 1)

This appears to be a table presenting the reduction in CHD Rates (events per 1000 patients) in the Helsinki Heart Study over a period of 5 years, with different baseline lipid values. The table shows the incidence of events among patients with different HDL-C and LDL-C values at baseline, divided into the placebo and gemfibrozil groups. The text also mentions that the events tracked over the period were fatal and non-fatal myocardial infarctions and sudden cardiac deaths.*

FDA Label Image

Table2 (Table 2)

The table shows the number of cardiac events and all-cause mortality (per 1000 patients) that occurred during the 3.5 year open-label follow-up to the Helsinki Heart Study. The data is organized into six groups (PDrop, PN, PG, GDrop, GN, GG), each identified by the original randomization (P = placebo, G = Gemfibrozil) and the drug taken in the follow-up period (N = Attend clinic but took no drug, G = Gemfibrozil, Drop = No attendance at clinic during open-label).*

FDA Label Image

Table3 (Table 3)

The table presents data on cardiac events, cardiac deaths, non-cardiac deaths, and all-cause mortality in the Helsinki Heart Study over a period of 8.5 years. The study compares the effects of gemfibrozil and placebo, and includes hazard ratios and confidence intervals. The analysis is based on the originally randomized patients, ignoring open-label treatment switches and exposure to study conditions. The events include fatal and non-fatal myocardial infarctions and sudden cardiac deaths.*

FDA Label Image

Label Image (Lbl500905808)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.